BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 40 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 4,895.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500 | $825,000 | 0.55% |
| SABBY MANAGEMENT, LLC | 136,484 | $27,310 | 0.02% |
| LIBERTY WEALTH MANAGEMENT LLC | 352,619 | $71 | 0.02% |
| Weaver Consulting Group | 99,356 | $19,881 | 0.01% |
| ABNER HERRMAN & BROCK LLC | 145,500 | $29 | 0.00% |
| JMAC ENTERPRISES LLC | 65,430 | $13,093 | 0.00% |
| Professional Financial Advisors, LLC | 17,279 | $3,458 | 0.00% |
| Ikarian Capital, LLC | 90,242 | $18,057 | 0.00% |
| MOORE CAPITAL MANAGEMENT, LP | 200,000 | $40,020 | 0.00% |
| Weaver Consulting Group | 45,000 | $2,750 | 0.00% |